Display search results for ** instead (33 products)

Showing 1-10 of 33

This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.

USD 450.00

USD 337.50 save 25 %

As 2013 transitions into 2014, the Manufacturing Leadership team offers 10 issues that should be top of mind for manufacturers in the new year.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.

USD 450.00

USD 337.50 save 25 %

In early November 2013, Frost & Sullivan conducted an online survey, followed up by a live focus group with about 20 C-suite executives from leading commercial payer organizations across the US. The goal was to gain insights into how the health insurance industry is approaching the use of analytics solutions going into 2014. Analytics solutions we...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.

USD 450.00

USD 337.50 save 25 %

06 Apr 2014  |  North America

Vital Signs - What’s New in Medical Imaging Advanced Visualization?

Evolving Customer Demands Spurring Competitive Dynamics

Ongoing technology and clinical advances in every imaging modality continue to bring advanced visualization (AV) and clinical applications to centerstage. AV is not just a core step in the interpretation workflow of each of these modalities, but essentially the set of solutions that allows to realize the promises of the advances on the equipment si...

USD 450.00

USD 337.50 save 25 %

Healthcare systems across the globe are facing rising operation costs, shortage of skilled labor and budgetary restraints, which has resulted in reduction in efficiency and quality of care. An increasing aging population, need for chronic disease management and providing access to healthcare for the geographically fragmented population demands the ...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.

USD 450.00

USD 337.50 save 25 %

11 Jun 2014  |  North America

Vital Signs - Value Emerging as a New Currency in Medical Imaging Markets

Value Based Imaging

The concept of value-based imaging is certainly not new, but it has garnered considerable attention from the medical imaging community over the past few years. Confined until recently to the realm of thought leaders at luminary healthcare and advocacy organizations, the concept has gained wide momentum in the past year. Since medical imaging repres...

USD 450.00

USD 337.50 save 25 %

Showing 1-10 of 33